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http:WHAT THIS PAPER ADDS
Two major types of silver-coated vascular prostheses with anti-bacterial properties are currently available:
Intergard Silver (IS) and Silver Graft (SG). They differ markedly in terms of their silver release kinetics. In the
present study, the angiogenic and inﬂammatory host tissue response to both types of prostheses was analyzed
in a chronic in vivo model during the ﬁrst 14 days after implantation. This is of particular interest, because
insufﬁcient early integration of vascular prostheses is considered to contribute to perigraft seroma formation
and subsequent infection. It was found that silver acetate-coated IS exhibits an improved vascularization and
reduced perigraft inﬂammation when compared with vaporized metallic silver-coated SG. Accordingly, the risk
for this mechanism of infection may be reduced for IS vascular graft implants.Objectives: In vascular surgery, the infection of prosthetic vascular grafts represents a serious life-threatening
complication. Due to the increasing resistance of hospital micro-organisms to standard antibiotic therapies,
maximum effort should be put in the primary prevention of such infections. For this purpose, grafts may be
coated with different antibacterial silver formulations. In the present study the different effects of silver acetate-
coating and vaporized metallic silver-coating on the vascularization and perigraft inﬂammation during the initial
phase after implantation of Intergard Silver (IS) and Silver Graft (SG) were compared.
Methods: Silver acetate-coated IS and vaporized metallic silver-coated SG were implanted into the dorsal skinfold
chamber of C57BL/6 mice (n ¼ 8 per group) to study angiogenesis and leukocyte inﬂammation at the
implantation site by means of repetitive intravital ﬂuorescence microscopy over a 14-day period. At the end of
the in vivo experiments, apoptosis and cell proliferation in the newly developed granulation tissue surrounding
the implants was analyzed by immunohistochemistry.
Results: IS exhibited an improved vascularization, resulting in a signiﬁcantly higher functional capillary density
when compared to SG. Moreover, the leukocyte inﬂammatory response to IS was less pronounced, as indicated
by a reduced number of adherent leukocytes in perigraft venules. This was associated with a higher proliferative
activity of the granulation tissue incorporating the IS when compared to SG. The numbers of apoptotic cells in the
perigraft tissue were low and did not differ between the two groups.
Conclusion: Silver acetate-coated IS exhibits an improved vascularization and reduced perigraft inﬂammation
during the ﬁrst 14 days after implantation when compared to vaporized metallic silver-coated SG. This may
contribute to reducing the risk of early perigraft seroma formation and subsequent infection.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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A major problem associated with synthetic vascular pros-
theses is the risk of bacterial infections, mostly sustained by
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//dx.doi.org/10.1016/j.ejvs.2014.03.006such infections has not changed much over the past two
decades, with continuing high morbidity and mortality
rates.2,3 Moreover, consensus about the optimal treatment
of vascular graft infections is still lacking.4,5 The complex
multimorbidity of vascular disease patients with infections
makes it difﬁcult to draw valid conclusions from clinical
research studies.6,7
In the past, many efforts have been made to identify
appropriate coatings for vascular prostheses that are re-
fractory to bacterial adhesion.8e11 As a consequence, two
types of silver-coated vascular prostheses have been
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Maquet, Rastatt, Germany) and Silver Graft (SG; B. Braun,
Melsungen, Germany). IS is a silver acetate-coated polyester
graft that releases substantial amounts of silver into the
surrounding tissue within the ﬁrst 2e3 weeks. Of interest,
we have recently demonstrate that this promotes the early
vascularization of the grafts without inducing inﬂammatory
side effects at the implantation site.12 Early vascularization
is, in turn, considered as an essential prerequisite for
adequate incorporation of prosthetic vascular grafts into
the surrounding tissue, reducing the risk of perigraft seroma
formation and subsequent infection.13e15
In contrast, SG is a vaporized metallic silver-coated
polyester graft that only releases marginal amounts of sil-
ver in the perigraft tissue during the ﬁrst 12 months after
implantation.11 Up to now, it is unknown how the type of
silver coating affects the early angiogenic and inﬂammatory
host tissue response to the grafts. Accordingly, SG and IS
were implanted into the dorsal skinfold chamber of mice to
analyze angiogenesis and inﬂammation of the perigraft
tissue using intravital ﬂuorescence microscopic and immu-
nohistochemical techniques.MATERIALS AND METHODS
Animals
For the experiments a total of 16 C57BL/6 mice (12e16
weeks old, 24e26 g; standard inbred laboratory mouse
strain from Charles River Laboratories GmbH, Sulzfeld,
Germany) were used. C57BL/6 mice have been used by us
and other groups in many former dorsal skinfold chamber
studies focusing on the interaction of various biomaterials
with the surrounding host tissue.12,16 They were housed
one per cage and had free access to tap water and standard
pellet food (Altromin, Lage, Germany) throughout the study
period.
All experiments were conducted in accordance with the
German legislation on protection of animals and the NIH
Guidelines for the Care and Use of Laboratory Animals (NIH
Publication #85-23 Rev. 1985). They were approved by the
local governmental animal care committee.Implantation of vascular grafts into the dorsal skinfold
chamber
The mouse dorsal skinfold chamber as a model for in vivo
testing of implanted vascular grafts and its preparation has
previously been described in detail.12,16 In the present
study, the two silver-coated, clinically used synthetic
vascular prostheses IS and SG, which were kindly provided
by Maquet and B. Braun, were implanted. SG is a warp-
knitted, double-velour vascular prosthesis made of poly-
ester (polyethylene terephthalate) that is impregnated with
modiﬁed bovine gelatin (polygelin). IS is a knitted polyester
prosthesis that is impregnated with collagen. Both im-
pregnations prevent the passage of blood components into
the surrounding tissue. Accordingly, the water permeability
of the prostheses is 5 mL  cm2  min1/120 mmHg. IScontains silver acetate in the collagen layer and in the graft
material itself, which leads to substantial silver release
during the ﬁrst 2e3 weeks after implantation followed by a
sustained release thereafter. In contrast, SG retains w80%
of its vaporized metallic silver coating during the ﬁrst 12
months. Thus, effective silver release within the ﬁrst 14 days
after implantation does not occur.11 The amount of silver
coated on the two prostheses is comparable (IS 0.06e
0.18 mg/cm2 and SG 0.07e0.16 mg/cm2).
The vascular prostheses were implanted 48 hours after
preparation of the dorsal skinfold chamber under labora-
tory conditions in an operating theatre for small animals at
the Institute for Clinical and Experimental Surgery, Univer-
sity of Saarland. All implantations were performed by the
same scientist. For this purpose, the mice were anes-
thetized by an intraperitoneal injection of 75 mg/kg keta-
mine hydrochloride (Ketavet; Parke Davis, Freiburg,
Germany) and 25 mg/kg dihydroxylidinothiazine hydro-
chloride (Rompun; Bayer, Leverkusen, Germany) and ﬁxed in
the right lateral decubital position on a Plexiglas stage. The
coverslip of the chamber was temporarily removed and
2 mm2 piece of either IS (weight: 1.48  0.04 mg) or SG
(1.94  0.05 mg) was carefully placed with the exterior side
onto the striated muscle tissue within the center of each
chamber, taking care to avoid contamination, mechanical
irritation, or damage to the chamber preparation.Intravital ﬂuorescence microscopy and microcirculatory
analysis
For intravital ﬂuorescence microscopy, the anesthetized
mice received an intravenous injection of 0.05 mL of 5%
ﬂuorescein isothiocyanate (FITC)-labeled dextran (molecular
weight: 150,000 Da; Sigma-Aldrich, Taufkirchen, Germany)
for the visualization of the intravascular space and 0.05 mL
1% rhodamine 6G (Sigma-Aldrich) for the in vivo staining of
leukocytes in postcapillary and collecting venules at the
implantation site. Subsequently, the mice were positioned
under a Zeiss Axiotech microscope (Zeiss; Oberkochen,
Germany) equipped with a camera and DVD recording
system, as previously described in detail.12
The microscopic images were analyzed quantitatively by
means of the computer-assisted off-line analysis system
CapImage (Zeintl, Heidelberg, Germany). Angiogenesis was
analyzed in eight different microvascular regions of interest
(ROIs; size 0.4 mm2), which were directly located at the
interface between the prosthetic vascular grafts and the
surrounding host tissue. The extent of vascular ingrowth
into the different ROIs was assessed by the quantitative
measurement of the functional capillary density, i.e. the
length of blood-perfused capillaries per observation area
and is given in cm/cm2.17
In four different ROIs in the border zone of the prosthetic
vascular grafts, that is in close vicinity to the implanted
material, we additionally measured leukocyteeendothelial
cell interaction and microhemodynamics in postcapillary
and collecting venules of the host tissue. For this purpose,
rhodamine 6G-stained leukocytes were classiﬁed according
Figure 1. (A, B) Intravital ﬂuorescent microscopic images at the border of an Intergard Silver (IS) (A, asterisk) and a Silver Graft (SG) implant
(B, asterisk) at day 14 after implantation into the dorsal skinfold chamber of C57BL/6 mice. Note the high density of newly formed
microvessels at the border of IS (A, arrows), overgrowing the striated muscle capillaries of the host tissue. SG shows only few newly formed
microvessels without overgrowth of the host microvasculature (B). Thus, the parallel arranged autochthonous muscle capillaries can still be
detected (arrowheads, B). Blue light epi-illumination with contrast enhancement by 5% FITC-labeled dextran 150,000 i.v. (C) Functional
capillary density (cm/cm2) within the border of IS (white bars; n ¼ 8) and SG implants (black bars; n ¼ 8), as assessed by intravital
ﬂuorescence microscopy and computer-assisted image analysis. Means  SEM. *p < .05 versus IS implants.
682 P. Jeanmonod et al.to their interaction with the vascular endothelium as
adherent, rolling, or free-ﬂowing cells.18 Adherent leuko-
cytes were deﬁned in each vessel segment as cells that did
not move or detach from the endothelial lining within a
speciﬁed observation period of 20 seconds, and are given as
number of cells per square millimeter of endothelial sur-
face, calculated from the diameter and length of the vessel
segment studied, assuming a cylindrical vessel geometry.
Rolling leukocytes were deﬁned as cells moving with a ve-
locity less than two-ﬁfths of the centerline velocity, and are
given as number of cells per minute, passing a reference
point within the microvessel.19
Diameters, centerline red blood cell (RBC) velocity,
volumetric blood ﬂow, and wall shear rate were determined
in those venules, in which leukocyteeendothelial cell
interaction was analyzed. Diameters (d) were measured in
micrometers perpendicularly to the vessel path. Centerline
velocity (v) was analyzed by the computer-assisted imageanalysis system using the line shift method.20 Volumetric
blood ﬂow was calculated by Q ¼ p  (d/2)2  v/1.6 [pL/s],
where 1.6 represents the BakereWayland factor to correct
for the parabolic velocity proﬁle in microvessels.21 More-
over, wall shear rate (y) was calculated based on the
Newtonian deﬁnition: y ¼ 8  v/d (given per second).
Experimental protocol
Samples of IS (n ¼ 8) and SG (n ¼ 8) were implanted into
the dorsal skinfold chamber of 16 C57BL/6 mice. Intravital
ﬂuorescence microscopic analyses of angiogenesis, leuko-
cyteeendothelial cell interaction, and microhemodynamics
were performed immediately as well as 3, 6, 10, and 14
days after implantation. At the end of the in vivo experi-
ments, the animals were sacriﬁced with an overdose of the
anesthetics, and the dorsal skinfold chamber preparations
were carefully excised for further immunohistochemical
analyses.
Table 1. Diameter (mm), centerline red blood cell velocity (mm/s), volumetric blood ﬂow (pL/s) and wall shear rate (s1) of postcapillary and
collecting venules within the border zones of IS (n ¼ 8) and SG implants (n ¼ 8) immediately (d0) as well as 3, 6, 10, and 14 days after
implantation into dorsal skinfold chamber of C57BL/6 mice. Means  SEM.
d0 d3 d6 d10 d14
Diameter (mm)
IS 28.1  1.4 30.1  2.0 27.2  1.5 27.8  1.6 24.5  1.1
SG 24.4  0.7 23.1  0.5 23.3  1.1 23.2  1.2 25.4  1.0
Centerline RBC velocity (mm/s)
IS 174.1  15.4 259.4  5.2 272.0  15.9 336.6  20.1 323.5  19.9
SG 108.6  10.5 233.5  16.8 262.9  16.1 312.8  19.6 315.3  30.3
Volumetric blood ﬂow (pL/s)
IS 71.6  18.7 115.2  14.0 85.9  10.9 103.6  17.0 84.5  6.8
SG 32.4  3.1 63.1  4.8 76.1  11.8 85.8  9.8 113.7  6.1
Shear rate (s1)
IS 61.3  6.8 81.0  7.7 79.8  7.1 94.0  7.3 89.0  4.9
SG 36.4  4.5 81.9  6.3 91.2  4.6 110.8  10.4 98.1  11.4
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At day 14 after the implantation of prosthetic vascular
grafts, formalin-ﬁxed specimens of the dorsal skinfold
preparations were embedded in parafﬁn and 3-mm-thick
sections were cut. For immunohistochemical detection of
apoptotic cells, cleaved caspase-3 (casp-3) staining was
performed using a rabbit polyclonal anti-casp-3 antibody
(1:100; New England Biolabs, Frankfurt, Germany) followed
by a biotin-conjugated goat anti-rabbit antibody (abcam;
Cambridge, UK) and streptavidin peroxidase. Proliferating
cells were detected by a mouse monoclonal anti-
proliferating cell nuclear antigen (PCNA) antibody (1:100;
Dako GmbH, Hamburg, Germany) as primary antibody fol-
lowed by a horseradish peroxidase-conjugated goat anti-
mouse antibody (1:100; Dianova, Hamburg, Germany).
3,30 Diaminobenzidine was the chromogen used. The sec-
tions were counter-stained with hemalaun and examined by
light microscopy (BX60; Olympus, Hamburg, Germany).
Casp-3- and PCNA-positive cells were assessed in nine high
power ﬁelds (HPFs) per section and are given as percentage
of the total number of cells per HPF.Statistics
After testing the data for normal distribution and equal
variance, differences between the two groups were
analyzed by an unpaired Student t test (SigmaStat; Jandel
Corporation, San Rafael, CA, USA). All values are expressed
as mean  standard error of the mean (SEM). Statistical
signiﬁcance was accepted for a p < 0 05.
RESULTS
Vascularization of prosthetic vascular grafts
The two types of synthetic vascular grafts induced an
angiogenic host tissue response in the dorsal skinfold
chamber. Microvascular sprout formation originating from
host capillaries and venules in the border zones of the grafts
could already be observed 3 days after implantation. During
the following days, the sprouts progressively grew into the
surrounding of the grafts’ surface to ﬁnally form newmicrovascular networks (Fig. 1A, B). Of interest, angiogen-
esis and perigraft vascularization were markedly pro-
nounced in IS grafts, which exhibited a signiﬁcantly higher
functional capillary density in the border zones at days 6,
10, and 14 than the SG (Fig. 1C).Microhemodynamics at the implantation site
Venules in the direct vicinity of the vascular grafts exhibited
a diameter of 23e30 mm (Table 1). The RBC velocity within
these vessels was between 109 and 323 mm/s throughout
the observation period. Accordingly, calculated values of
volumetric blood ﬂow and wall shear rate were 32e115 pL/
s and 36e111 per second (Table 1). There were no signiﬁ-
cant differences between the two experimental groups,
indicating comparable microhemodynamic conditions for
the analysis of leukocyteeendothelial cell interaction as a
parameter for the inﬂammatory response to the implants.Leukocyteeendothelial cell interaction at the implantation
site
During the observation period of 14 days, the numbers of
rolling leukocytes in postcapillary and collecting venules
ranged between 4.8 and 8.9 min1 without signiﬁcant dif-
ferences between the IS and the SG group (Fig. 2AeC).
However, the numbers of adherent leukocytes were signif-
icantly higher in SG implants than IS grafts, indicating a
stronger inﬂammatory activation of leukocytes in the peri-
graft host tissue (Fig. 2D).Cell proliferation and apoptosis in the perigraft tissue
After the observation period of 14 days, immunohisto-
chemical detection of PCNA showed a signiﬁcantly higher
number of proliferating cells in the granulation tissue sur-
rounding the IS grafts compared to that of SG implants
(Fig. 3). In contrast, the numbers of apoptotic cells in the
perigraft tissue were low without marked differences be-
tween the two groups (Fig. 4).
Figure 2. (A, B) Intravital ﬂuorescent microscopic images of collecting venules in the direct vicinity of Intergard Silver (IS) (A) and Silver
Graft (SG) implants (B) at day 14 after implantation into the dorsal skinfold chamber of C57BL/6 mice. Green light epi-illumination for the
detection of adherent rhodamine 6G-stained leukocytes (arrows). (C, D) Rolling leukocytes (C, min1) and adherent leukocytes (D, mm2)
in postcapillary and collecting venules within the border zones of IS (white bars; n ¼ 8) and SG implants (black bars; n ¼ 8), as assessed by
intravital ﬂuorescence microscopy and computer-assisted image analysis. Means  SEM. *p < .05 versus IS implants.
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Figure 3. (A, B) Immunohistochemical cross sections of the border zones of an Intergard Silver (IS) (A) and a Silver Graft (SG) implant (B) at
day 14 after implantation onto the striated muscle tissue within the dorsal skinfold chamber of C57BL/6 mice. The sections were stained
with an antibody against PCNA for the visualization of proliferating cells (arrows). C: PCNA-positive cells (%) in the border zones of IS (white
bars; n ¼ 8) and SG implants (black bars; n ¼ 8) at day 14 after implantation. Means  SEM. *p < .05 versus IS implants.
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According to the data of Moran et al.22 and Ali et al.,23
infection rates of autologous venous and arterial grafts
are generally low. In contrast, the implantation of synthetic
vascular prostheses is associated with a relative high risk of
infections with devastating complications, including anas-
tomotic disruption with massive hemorrhage and pseu-
doaneurysm formation, graft thrombosis, limb loss, and
high perioperative and late mortality.24,25 For the preven-
tion of such infections, the antibacterial silver-coated
vascular grafts IS and SG have been introduced into clin-
ical practice, which markedly differ in terms of their silver-
release rates.26,27 Silver acetate-coated IS rapidly releases
silver into the surrounding tissue within the ﬁrst 2e3
weeks. Thus, these prostheses exhibit a time limited anti-
microbial efﬁcacy.28,29 SG is coated with vaporized metallic
silver that is only released to a negligible extent during the
ﬁrst 12 months after implantation.11 Accordingly, the anti-
bacterial efﬁcacy of its surface remains intact much longer,
but the graft is less protective in the surrounding tissue
against bacterial infections.11,30 In the present study,evidence is provided for the ﬁrst time that the differences
between the two vascular prostheses crucially determine
the early angiogenic and inﬂammatory host tissue response.
The aim of the present study was to compare two silver-
coated prostheses with different release kinetics. For this
purpose it would have been much better to use two pros-
theses from the identical manufacturer produced in an
identical manner, which solely differ in their silver release
kinetics. However, unfortunately this was not possible,
because such prostheses are not available on the market.
Accordingly, two silver-coated prostheses from different
manufacturers, which are currently widely used in clinical
practice were compared.
In a previous study it has already been demonstrated that
silver acetate-coated IS exhibits improved vascularization
compared with uncoated grafts,12 which may be caused by
direct pro-angiogenic silver effects, such as the stimulation
of cellular vascular endothelial growth factor production
and reactive oxygen species formation.12,31 Besides the
well-known antibacterial properties of silver,32 this obser-
vation may further contribute to the prevention of in-
fections by an improved early graft incorporation into the
Figure 4. (A, B) Immunohistochemical cross sections of the border zones of an Intergard Silver (IS) (A) and a Silver Graft (SG) implant (B) at
day 14 after implantation onto the striated muscle tissue within the dorsal skinfold chamber of C57BL/6 mice. The sections were stained
with an antibody against casp-3 for the visualization of apoptotic cells (arrows). (C) Casp-3-positive cells (%) in the border zones of IS (white
bars; n ¼ 8) and SG implants (black bars; n ¼ 8) at day 14 after implantation. Means  SEM.
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not the case for vaporized metallic silver-coated SG. In fact,
in the dorsal skinfold chamber model, SG exhibited a
signiﬁcantly reduced vascularization during the ﬁrst 14 days
after implantation when compared to IS. Accordingly, a
markedly decreased number of PCNA-positive cells in the
newly developing granulation tissue surrounding the SG
grafts was also observed. This indicates that the extent of
vascularization directly correlates with the incorporation of
the grafts at the implantation site. Further studies are
required to clarify whether this is also the case after longer
observation periods.
In addition, it was found that throughout the observation
period of 14 days there were an increased number of
adherent leukocytes in postcapillary and collecting venules
in the direct vicinity of SG when compared to IS. Because
the analyzed microvessels of both experimental groups
exhibited a comparable diameter, centerline RBC velocity,
volumetric blood ﬂow, and wall shear rate, this increased
leukocyteeendothelial cell interaction may not be attrib-
uted to different microhemodynamic conditions, but is due
to a more pronounced leukocyte inﬂammatory reaction.Therefore, it may be concluded that despite its very low
release rate the vaporized metallic silver of SG activates
pro-inﬂammatory mechanisms at the implantation site.
Nonetheless, SG grafts have still to be considered as
biocompatible, because the number of adherent leukocytes
was constantly <300/mm2, which is far below the typical
values of adherent leukocytes in severely inﬂamed dorsal
skinfold chambers (>700/mm2).17,34,35 Moreover, both
experimental groups presented with low numbers of casp-
3-positive apoptotic cells in the perigraft granulation tis-
sue, further indicating the lack of direct cytotoxic effects of
the different silver coatings of IS and SG.CONCLUSION
Insufﬁcient integration of a vascular prosthesis due to
inadequate neovascularization may contribute to perigraft
seroma formation and subsequent infection.13e15 The pre-
sent study demonstrates that silver acetate-coated IS ex-
hibits an improved vascularization and reduced perigraft
inﬂammation during the ﬁrst 14 days after implantation
when compared to vaporized metallic silver-coated SG.
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